SCHEMBL25933034

SCHEMBL25933034

Cc1ccc(Oc2ccc(-c3nn(C4CCN(C(C)(C)C)CC4)c4ncnc(N)c34)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 14/20 0.68
▸ NUDT14 O95848 1/20 0.68
▸ NUDT5 Q9UKK9 1/20 0.68
▸ LCK P06239 6/20 0.64
▸ LYN P07948 2/20 0.64
▸ SRC P12931 8/20 0.61
▸ KDR P35968 2/20 0.61
▸ TEK Q02763 2/20 0.61
▸ EGFR P00533 3/20 0.58
▸ CSK P41240 3/20 0.57
▸ KDM4E B2RXH2 1/20 0.57
▸ PLK4 O00444 1/20 0.57
▸ RIPK2 O43353 1/20 0.57
▸ ROCK2 O75116 1/20 0.57
▸ PRKD3 O94806 1/20 0.57
▸ MAP4K4 O95819 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ ABL1 P00519 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ ERBB2 P04626 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25933036 0.92 BTK (0.68) BTKNUDT14NUDT5LCKLYN
SCHEMBL24827777 0.92 BTK (0.80) BTKNUDT14NUDT5LCKLYN
SCHEMBL25466285 0.91 BTK (0.67) BTKNUDT14NUDT5LCKLYN
SCHEMBL25478186 0.90 BTK (0.65) BTKNUDT14NUDT5LCKLYN
SCHEMBL24197177 0.89 BTK (0.85) BTKNUDT14NUDT5LCKLYN
SCHEMBL29439184 0.89 BTK (0.76) BTKNUDT14NUDT5LCKLYN
SCHEMBL25466299 0.87 BTK (0.80) BTKNUDT14NUDT5LCKLYN
SCHEMBL25933030 0.87 BTK (0.75) BTKNUDT14NUDT5LCKLYN
SCHEMBL25470600 0.86 SRC (0.71) BTKNUDT14NUDT5LCKLYN
SCHEMBL24197056 0.86 BTK (0.68) BTKNUDT14NUDT5LCKLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 — — US disclosed
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR BTK, WEE1, WEE2 BTK 1/4885NUDT14 3438/4885NUDT5 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback